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Abstract
The statistics related to pregnancy and its outcomes are staggering: annually, an estimated 250000-280000 women
die during childbirth. Unfortunately, a large number of women receive little or no care during or before pregnancy.
At a period of critical vulnerability, interventions can be effectively delivered to improve the health of women and
their newborns and also to make their pregnancy safe. This paper reviews the interventions that are most effective
during preconception and pregnancy period and synergistically improve maternal and neonatal outcomes. Among
pre-pregnancy interventions, family planning and advocating pregnancies at appropriate intervals; prevention and
management of sexually transmitted infections including HIV; and peri-conceptual folic-acid supplementation have
shown significant impact on reducing maternal and neonatal morbidity and mortality. During pregnancy,
interventions including antenatal care visit model; iron and folic acid supplementation; tetanus Immunisation;
prevention and management of malaria; prevention and management of HIV and PMTCT; calcium for hypertension;
anti-Platelet agents (low dose aspirin) for prevention of Pre-eclampsia; anti-hypertensives for treating severe
hypertension; management of pregnancy-induced hypertension/eclampsia; external cephalic version for breech
presentation at term (>36 weeks); management of preterm, premature rupture of membranes; management of
unintended pregnancy; and home visits for women and children across the continuum of care have shown
maximum impact on reducing the burden of maternal and newborn morbidity and mortality. All of the
interventions summarized in this paper have the potential to improve maternal mortality rates and also contribute
to better health care practices during preconception and periconception period.
Introduction
Although maternal mortality has decreased during the
past decade, the proportion of births attended by a skilled
health personnel still remains 68% in developing regions,
often leading to tragic consequences [1]. Annually, an esti-
mated 250000-280000 women die during childbirth [2]
while over 15 million are chronically afflicted with compli-
cations which occur during pregnancy [3]. Adressing these
issues in developing regions are critical forimproving
maternal and neonatal health status and decreasing the
associated morbidity and mortality.
In order to attain optimum level of health during preg-
nancy and the best possible maternal and neonatal health
outcomes, effective interventions need to be delivered
during preconception period and throughout pregnancy.
In recent years, there has been increaased awareness
regarding the importance of preconception period and
efforts have been made to increase awareness and pro-
mote health right from childhood and adolescence
onwards [4-12]. Research has also established linkages of
preconception interventions with improved maternal,
perinatal and neonatal health outcomes and it has been
suggested that several proven interventions recom-
mended during pregnancy may be even more effective if
implemented before conception. On the other hand,
interventions delivered during pregnancy also play a defi-
nitive beneficial role for improved maternal, fetal and
neonatal health and survival. Maternal undernutrition,
infections and chronic diseases carry a high risk for poor
maternal and neonatal health and therefore, regular ana-
tenatal checkups with improved screening can save many
maternal and neonatal lives.
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The motive of this review is to highlight the effectiveness
of essential pre-pregnancy and pregnancy interventions
that have an alleged impact on maternal, fetal and new-
born outcomes and can be suitably delivered to low and
middle income countries (LMIC) where minimal essential
care is generally available.
Methodology
The methodology has been described in detail elsewhere
[13]. In short, the review included all pre-pregnancy and
pregnancy interventions based on current World Health
Organization (WHO) guidelines and recent Lancet series
which have an alleged impact on reducing maternal, neo-
natal and child mortality; suitable for delivery in LMICs,
and those that can be delivered through the health sector
(community level up to the referral level of health care)
(Table 1). All relevant pre-pregnancy and pregnancy inter-
vention reviews were identified from the electronic data-
bases and were classified according to evidence and
delivery strategies. Search was conducted in the following
electronic databases: the Cochrane database of systematic
reviews, the Cochrane database of abstract reviews of
effectiveness (DARE), theCochrane database of systematic
reviews of randomized control trials (RCT’s), and PubMed.
The reference lists of the reviews and recommendations
from experts in the field were also used as sources to
obtain additional publications. The principal focus was on
the existing systematic reviews and meta-analysis. Based
on the efficiency of the interventions, these were then clas-
sisifed in categories from A to E (where A signified
strongly beneficial effect while E indicated harmful effect)
on different levels of health sector (community/outreach/
referral).
Results
Pre-pregnancy interventions
Family planning
There is a large unmet need for family planning as at least
200 million women desire safe and effective family plan-
ning methods.An estimated 21.6million unsafe abortions
took place worldwide in 2008, almost all in LMICs. Num-
bers of unsafe abortions have increased from 19.7 million
in 2003 although the overall unsafe abortion rate remains
unchanged at about 14 unsafe abortions per 1000 women
aged 15–44 years [14]. Family planning prevents unwanted
pregnancies and eliminates recourse to abortions. Both
short and long inter-pregnancy intervals are associated
with adverse perinatal outcomes [15-17] such as preterm
birth, low birth weight (LBW), small for gestational age
(SGA) and perinatal death. This link, however, may be
confounded by different maternal characteristics and
socio-economic status. To prevent these adverse events,
birth spacing may be considered an intervention, especially
in the developing world. Family planning is to plan when
to have children and the use of birth control to delay preg-
nancy, including other techniques to implement such
plans. Family planning services are defined as educational,
comprehensive medical or social activities which enable
individuals, including minors, to determine freely the
number and spacing of their children and to select the
means by which this may be achieved.
Short inter-pregnancy interval (IPIs) (less than 6
months) is associated with higher risk of preterm birth
(odds ratio (OR) 1.40; 95% confidence interval (CI): 1.24,
1.58), LBW (OR 1.61; 95% CI: 1.39, 1.86), fetal death (OR
1.54, 95% CI: 1.06, 1.96) and SGA (OR 1.26; 95% CI: 1.18,
1.33) compared to IPI of 18 to 23 months. The risk is
also significantly increased for these three adverse out-
comes if the infant is conceived 60 months or more after
a birth (preterm birth: OR 1.20; 95% CI: 1.17, 1.24; LBW:
OR 1.43; 95% CI: 1.27, 1.62; fetal death OR 1.21, 95% CI:
1.07, 1.31 and SGA: OR 1.29; 95% CI: 1.20, 1.39) [18-20].
A recently published review with modified interval win-
dow reported the similar findings [21]. Birth interval of
shorter than 18 months was associated with increased
odds of SGA (OR 1.51, 95% CI: 1.31, 1.75), preterm (OR:
1.58, 95% CI: 1.19, 2.10) and infant mortality (OR 1.83,
95% CI: 1.19, 2.81) as compared to IPI of 36 to <60
months. On the other hand, birth interval over 60
months had increased risk of SGA (OR: 1.22, 95% CI:
1.07, 1.39) and term-SGA (OR: 1.14, 95% CI: 1.03, 1.27)
when compared with IPI of 36 to <60 months. The effi-
cacy and effectiveness for different methods of contra-
ception were also compared. The efficacy of the
withdrawal method was found to be maximum (4%) and
the least one was for the implant (0.1%), while the effec-
tiveness was 21.6% for periodic abstinence and 15.1% for
withdrawal [22]. These findings suggest that short IPIs
(less than 6 months) are associated with a significantly
higher risk of preterm birth, LBW, fetal death and SGA
infants compared to IPIs of 18 to 23 months. A recent
review also reported higher risk of SGA, preterm births
and infant mortality with IPIs of less than 18 months
compared to 36 to <60 months. However, the risks were
also higher if the infant is conceived 60 months or more
after a birth. It is therefore advisable to plan pregnancies
at appropriate intervals.
Prevention and management of sexually transmitted
infections (STIs) including HIV
HIV was first declared as a pandemic in the early 1980s
and the virus has become the leading cause of mortality
across the globe, and the number of people it has infected
and killed worldwide is astonishing. HIV is mainly spread
in the population through sexual intercourse, needle shar-
ing, blood transfusion or vertical transmission, which is
the primary way by which children are infected. We
looked at the role of mass media, behavioural interven-
tions and biomedical interventions.
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Table 1 Characteristics of the included reviews on pre-pregnancy and pregnancy interventions
Reviews Objective Type of Studies
included (number)
Cochrane/non-
Cochrane
Pooled Data
(Y/N)
Outcomes reported
Conde-Agudelo 2007
[20]
To explore the association between birth spacing and
risk of adverse maternal outcomes
Observational studies =
22
Non-Cochrane Yes Pre-eclampsia, maternal outcomes
Conde-Agudelo 2007
[19]
To examine the association between birth spacing and
relative risk of adverse perinatal outcomes.
Observational studies =
67
Non-Cochrane Yes preterm birth, low birth weight, and small for
gestational age
Kozuki 2013 [21] To examine the association between short/long birth
intervals and adverse neonatal outcomes by calculating
and meta-analyzing associations using original data
from cohort studies conducted in low-and middle-
income countries.
Cohort =5 Non-cohrane Yes Small for gestational age, Infant mortality, Preterm
births
Anglemyer 2013 [23] To determine if ART use in an HIV-infected member of
an HIV-discordant couple is associated with lower risk
of HIV transmission to the uninfected partner
compared to untreated discordant couples.
Observational studies = 7 Cochrane Yes Episodes of HIV transmisison, index partner’s CD4
cell count.
Ng 2011 [24] To determine the impact of population-based
biomedical STI interventions on the incidence of HIV
infection.
RCT: 4 Cochrane Yes incident HIV infection, prevalence of syphilis
Blencowe 2010 [29] To review the evidence for, and estimate the effect of,
folic acid fortification/supplementation on neonatal
mortality due to NTDs, especially in low-income
countries.
RCT: 3
Observational studies: 8
Non-Cochrane Yes NTD recurrence, NTD incidence, congenital
abnormalities, neonatal deaths
De-Regil 2010 [30] This review examined whether folate supplementation
before and during early pregnancy can reduce neural
tube and other birth defects (including cleft palate)
without causing adverse outcomes for mothers or
babies.
RCTs: 5 Cochrane Yes Prevention of NTDs, incidence of NTDs,
reoccurrence of NTDs, cleft palate, cleft lip,
congenital cardiovascular defects, miscarriages or
any other birth defects.
Imdad 2011 [31] To evaluate the effectiveness of peri-conceptional folic
acid supplementation in reducing neural tube defects
(NTD), related stillbirths and balanced protein energy
and multiple micronutrients supplementation during
pregnancy in reducing all-cause stillbirths.
RCTs: 18 Non-Cochrane Yes NTDs, stillbirths
Carrolli 2001 [33] a systematic review of randomised trials assessing the
effectiveness of different models of antenatal care.
RCTs: 7 Non-Cochrane Yes pre-eclampsia, urinary-tract infection, postpartum
anaemia, maternal mortality, low birth weight
Dowswell 2010 [34] To compare the effects of antenatal care programmes
with reduced visits for low-risk women with standard
care.
RCTs: 7 Cochrane Yes Perinatal mortality, admission to neonatal intensive
care
Homer 2012 [35] The first objective was to compare the effects of group
antenatal care versus one-to-one care on outcomes for
women and their babies.
RCTs and q-RCTs : 2 Cochrane Yes Preterm birth, low birth weight, small-for-
gestational age and perinatal mortality.
Pena-Rosas 2012 [41] To assess the effects of daily oral iron supplements for
pregnant women, either alone or in conjunction with
folic acid, or with other vitamins and minerals as a
public health intervention.
RCTs and q-RCTs : 43 Cochrane Yes low birthweight, mean birth weight, maternal
anaemia, iron deficiency at term, side effects,
haemoglobin (Hb) concentrations
Yakoob 2011 [42] To address the impact of iron with and without folate
supplementation on maternal anemia and provides
outcome specific quality according to the Child Health
Epidemiology Reference Group (CHERG) guidelines.
RCTs and q-RCTs : 31 Non-Cochrane Yes incidence of anemia at term, iron deficiency
anemia at term
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Table 1 Characteristics of the included reviews on pre-pregnancy and pregnancy interventions (Continued)
Lassi 2013 [43] To assess the effectiveness of oral folic acid
supplementation alone or with other micronutrients
versus no folic acid (placebo or same micronutrients
but no folic acid) during pregnancy on haematological
and biochemical parameters during pregnancy and on
pregnancy outcomes.
RCTs and q-RCTs : 31 Cochrane Yes Preterm birth, stillbirths/neonatal deaths, mean
birthweight, anaemia, mean pre-delivery
haemoglobin level, mean pre-delivery serum folate
levels, mean pre-delivery red cell folate levels,
incidence of megaloblasticanaemia
Demicheli 2013 [47] To assess the effectiveness of tetanus toxoid,
administered to women of childbearing age or
pregnant women, to prevent cases of, and deaths
from, neonatal tetanus
RCTs: 2 Non-Cochrane No vaccine effectiveness was 43%
Blencowe 2010 [48] To review the evidence for and estimate the effect on
neonatal tetanus mortality of immunization with
tetanus toxoid of pregnant women, or women of
childbearing age.
RCT: 1
CT: 1
Non-Cochrane Yes mortality from neonatal tetanus
Garner 2006 [52] To assess drugs given to prevent malaria infection and
its consequences in pregnant women living in malarial
areas. This includes prophylaxis and intermittent
preventive treatment (IPT).
RCTs and q-RCTs : 16 Cochrane Yes antenatal parasitaemia, placental malaria, perinatal
deaths
TerKuile 2007 [53] To determine the effect of increasing resistance to
sulfadoxine-pyrimethamine on the efficacy of IPT
during pregnancy in Africa.
RCTs: 4 Non-Cochrane Yes placental malaria, low birth weight, anemia
Lengeler 2004 [54] To assess the impact of insecticide-treated bed nets or
curtains on mortality, malarial illness (life-threatening
and mild), malaria parasitaemia, anaemia, and spleen
rates.
RCTs: 22 Cochrane Yes protective efficacy, severe malaria, parasite
prevalence, high parasitaemia, splenomegaly (30%
PE), haemoglobin
Gamble 2007 [55] To compare the impact of ITNs with no nets or
untreated nets on preventing malaria in pregnancy
RCTs: 5 Non-Cochrane Yes low birthweight, stillbirths/abortions in the first to
fourth pregnancy
Gamble 2006 [56] To compare the impact of ITNs with no nets or
untreated nets on preventing malaria in pregnancy.
RCTS: 6 Cochrane Yes low birthweight, stillbirths/abortions in the first to
fourth pregnancy
Eisele 2010 [57] To estimate the effect of ITNs and IRS on preventing
malaria-attributable mortality in children 1–59 months,
and to estimate the effect of ITNs and IPTp on
preventing neonatal and child mortality through
improvements in birth outcomes.
RCTs: 14 Non-Cochrane Yes rotective efficacy, malaria-attributable mortality 1–
59 months, prevention interventions in pregnancy
Lumley 2009 [58] To assess the effects of smoking cessation
interventions during pregnancy on smoking behaviour
and perinatal health outcomes.
RCTs: 72 Cochrane Yes reduction in smoking in late pregnancy, relapse
Coleman 2012 [59] To determine the efficacy and safety of smoking
cessation pharmacotherapies, including NRT,
varenicline and bupropion (or any other medications)
when used to support smoking cessation in
pregnancy.
RCTs: 6 Cochrane Yes smoking cessation in later pregnancy
Blencowe 2011 [61] This review sought to estimate the effect of detection
and treatment of active syphilis in pregnancy with at
least 2.4MU benzathine penicillin (or equivalent) on
syphilis-related stillbirths and neonatal mortality.
Observational studies: 25 Non-Cochrane Yes Stillbirth, preterm delivery, neonatal deaths
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Table 1 Characteristics of the included reviews on pre-pregnancy and pregnancy interventions (Continued)
Walker 2001 [62] To identify the most effective antibiotic treatment
regimen (in terms of dose, length of course and mode
of administration) of syphilis with and without
concomitant infection with HIV for pregnant women
infected with syphilis.
RCTs and q-RCTs : 26 Cochrane No None matched predetermined criteria for
comparison
Wiysonge 2011 [65] To assess the effects of antenatal and intrapartum
vitamin A supplementation on the risk of MTCT of HIV
infection and infant and maternal mortality and
morbidity, and the tolerability of vitamin A
supplementation.
RCTs: 4 Cochrane Yes MTCT of HIV infection, birth weight, stillbirths,
preterm births, death by 24 months among live
births
Shey 2002 [66] To estimate the effect of vaginal lavage on the risk of
MTCT of HIV and infant and maternal mortality and
morbidity, as well as tolerability of vaginal lavage in
HIV infected women.
RCT: 1 Cochrane No vaginal disinfection on MTCT of HIV
Kesho Bora 2009 [64] Triple-antiretroviral (ARV) prophylaxis during pregnancy
and breastfeeding compared to short-ARV prophylaxis
to prevent mother-to-child transmission of HIV-1
(PMTCT): the Kesho Bora randomized controlled clinical
trial in five sites in Burkina Faso, Kenya
1 study in five different
location
Non Cochrane No Extended triple ARV regimen consisting of the anti-
HIV drugs zidovudine, lamivudine andlopinavir/
ritonavir, from the last trimester of pregnancy and
continued during breastfeeding up to the age of
six months.
Imdad 2011 [78] To evaluate preventive effect of calcium
supplementation during pregnancy on gestational
hypertensive disorders and related maternal and
neonatal mortality in developing countries.
RCTs: 10 Non-Cochrane Yes gestational hypertension, pre-eclampsia, neonatal
mortality
Hofmeyr 2010 [79] To assess the effects of calcium supplementation
during pregnancy on hypertensive disorders of
pregnancy and related maternal and child outcomes.
RCTs: 13 Cochrane Yes high blood pressure, pre-eclampsia, preterm birth,
stillbirth or death before discharge from hospital,
maternal death or serious morbidity
Jabeen 2011 [81] To review the effect of aspirin, calcium
supplementation, antihypertensive agents and
magnesium sulphate on risk stillbirths.
RCTs: 82 Non-Cochrane Yes stillbirths
Duley 2013 [83] To assess the effectiveness and safety of antiplatelet
agents for women at risk of developing pre-eclampsia.
RCTs: 59 Cochrane yes Yes pre-eclampsia, maternal risk, preterm birth, fetal or
neonatal deaths, small-for-gestational age babies
Askie 2007 [84] to assess the use of antiplatelet agents for the primary
prevention of pre-eclampsia, and to explore which
women are likely to benefit most.
RCTs: 31 Non-Cochrane Yes pre-eclampsia, of delivering before 34 weeks,serious
adverse outcome
Duley 2013 [88] To compare different antihypertensive drugs for very
high blood pressure during pregnancy.
RCTs: 24 Cochrane Yes persistent high blood, risk of HELLP, risk of
hypotension, eclampsia, respiratory difficulties, but
fewer side-effects, less postpartum haemorrhage
Magee 2003 [89] to assess whether oral beta-blockers are overall better
than placebo, or no beta-blocker, for women with
mild-moderate hypertension during pregnancy, and to
assess whether oral beta-blockers have any advantages
over other antihypertensive agents for women with
mild-moderate hypertension during pregnancy.
RCTs; 27 Cochrane Yes Both maternal outcomes (e.g., the incidence of
severe hypertension) and perinatal outcomes
Duley 2010 [90] The objective of this review was to assess the effects
of magnesium sulphate compared with diazepam
when used for the care of women with eclampsia.
Magnesium sulphate is compared with phenytoin and
with lytic cocktail in other Cochrane reviews.
RCTs: 7 Cochrane Yes Recurrence of seizures, maternal morbidity,
perinatal mortality, neonatal mortality, Apgar score
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Table 1 Characteristics of the included reviews on pre-pregnancy and pregnancy interventions (Continued)
Duley 2010 [91] The objective of this review was to assess the effects
of magnesium sulphate compared with phenytoin
when used for the care of women with eclampsia.
RCTs: 7 Cochrane Yes Recurrence of seizures, maternal morbidity,
perinatal mortality, neonatal mortality, Apgar score
Duley 2010 [92] To assess the effects of magnesium sulphate, and
other anticonvulsants, for prevention of eclampsia.
RCTs: 15 Cochrane Yes Eclampsia, maternal death, serious maternal
morbidity, placental abruption, caesarean section,
stillbirths
Duley 2010 [93] To assess the effects of magnesium sulphate compared
with lytic cocktail (usually chlorpromazine,
promethazine and pethidine) when used for the care
of women with eclampsia
RCTs: 3 Cochrane Yes maternal deaths, seizures, respiratory depression ,
coma, pneumonia
Cluver 2012 [95] To assess interventions such as tocolysis, fetal acoustic
stimulation, regional analgesia,
transabdominalamnioinfusion or systemic opioids on
ECV for a breech baby at term.
RCTs and qRCTs: 25 Cochrane Yes cephalic presentations in labour, caesarean sections
Hutton 2006 [96] To assess the effectiveness of a policy of beginning
ECV before term (before 37 weeks’ gestation) for
breech presentation on fetal presentation at birth,
method of delivery, and the rate of preterm birth,
perinatal morbidity, stillbirth or neonatal mortality.
RCTs: 3 Cochrane No non-cephalic presentation at birth
Hofmeyr 2012 [97] The objective of this review was to assess the effects
of postural management of breech presentation on
measures of pregnancyoutcome.We evaluated
procedures in which the motherrests with herpelvis
elevated. These include the knee-chestposition, and a
supin e position with the pelvis elevated with a
wedge-shaped cushion
RCTs: 6 Cochrane Yes non-cephalic births, Cesarean section and Apgar
scores below 7 at one minute, r
Hofmeyr 2012 [98] The objective of this review was to assess the effects
of ECV at or near term on measures of pregnancy
outcome. Methods of facilitatingECV, and ECV before
term are reviewed separately
RCTs: 7 Cochrane Yes non-cephalic presentation at birth, Cesarean section
Hofmeyr 2003 [99] To assess the effects of planned caesarean section for
singleton breech presentation at term on measures of
pregnancy outcome.
RCTs: 3 Cochrane Yes Caesarean delivery, perinatal or neonatal death or
serious neonatal morbidity, urinary incontinence,
abdominal pain , perineal pain
Coyle 2012 [100] To examine the effectiveness and safety of
moxibustion on changing the presentation of an
unborn baby in the breech position, the need for
external cephalic version (ECV), mode of birth, and
perinatal morbidity and mortality for breech
presentation.
RCTs: 3 Cochrane Yes need for ECV, use of oxytocin before or during
Buchanan 2010 [102] To assess the effect of planned early birth compared
with expectant management for pregnancies
complicated with PPROM prior to 37 weeks’ gestation.
RCTs: 7 Cochrane Yes neonatal sepsis, respiratory distress, incidence of
caesarean section
Kenyon 2010 [103] To evaluate the immediate and long-term effects of
administering antibiotics to women with pROM before
37 weeks, on maternal infectious morbidity, fetal and
neonatal morbidity and mortality, and longer term
childhood development.
RCTs: 19 Cochrane Yes Chorioamnionitis, neonatal morbidity, neonatal
infection, use of surfactant
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Table 1 Characteristics of the included reviews on pre-pregnancy and pregnancy interventions (Continued)
Cousens 2010 [104] To review the evidence for and estimate the effect on
neonatal mortality due to pre-term birth complications
or infection, of administration of antibiotics to women
with pPROM, in low and middle-income countries.
RCTs: 18 Non-Cochrane Yes respiratory distress syndrome , early onset postnatal
infection, neonatal mortality
Roberts 2006 [105] To assess the effects on fetal and neonatal morbidity
and mortality, on maternal mortality and morbidity,
and on the child in later life of administering
corticosteroids to the mother before anticipated
preterm birth.
RCTs: 22 Cochrane Yes chorioamnionitis or puerperal sepsis, neonatal
death, RDS, cerebroventricularhaemorrhage,
necrotisingenterocolitis
Mwansa-Kambafwile
2010 [108]
To review the evidence for and estimate the effect on
cause-specific neonatal mortality of administration of
antenatal steroids to women with anticipated preterm
labour, with additional analysis for the effect in low-
and middle-income countries.
Studies: 44
RCTs: 18
Non-Cochrane Yes neonatal mortality among preterm infant
Brownfoot 2008 [109] To assess the effects of different corticosteroid
regimens for women at risk of preterm birth.
RCTs: 10 Cochrane Yes Incidence of intraventricularhaemorrhage,
respiratory distress syndrome, bronchopulmonary
dysplasia, severe intraventricularhaemorrhage,
periventricular leukomalacia, perinatal death, or
mean birthweight.
WHO 2003 [113] evidence profiles related to the prioritized questions
were prepared, based upon recent systematic reviews,
most of which are included in the Cochrane Database
of Systematic Reviews
- - - -
Kidney 2009 [116] The objective was to provide a systematic review of
the effectiveness of community-level interventions to
reduce maternal mortality.
RCTs: 5
Cohort: 8
Non-Cochrane Yes Maternal mortality
Lassi 2010 [117] To assess the effectiveness of community-based
intervention packages in reducing maternal and
neonatal morbidity and mortality; and improving
neonatal outcomes.
RCTs and qRCTs: 18 Cochrane Yes Maternal mortality, neonatal mortality, perinatal
morality, stillbirths, newborn care practices
Gogia 2010 [118] To determine whether home visits for neonatal care by
community health workers can reduce infant and
neonatal deaths and stillbirths in resource-limited
settings.
RCTs: 5 Non-Cochrane Yes Neonatal death and stillbirth, and a significant
improvement in antenatal and neonatal practice
indicators (> 1 antenatal check-up, 2 doses of
maternal tetanus toxoid, clean umbilical cord care,
early breastfeeding and delayed bathing).
Bhutta 2009 [115] examines the evidence for community and health
systems approaches to improve uptake and quality of
antenatal and intrapartum care,
RCTs: 9 Non-Cochrane Yes Stillbirths
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A review of observational studies found that antiretero-
viral therapy (ART) use in an HIV-infected member of
an HIV-discordant couple is associated with lower risk of
HIV transmission to the uninfected partner compared to
untreated discordant couples (risk ratio (RR) 0.34; 95%
CI 0.13, 0.92) [23]. Mass treatment after three rounds of
treatment of all community members for STIs indicated
no effect of the intervention with the risk ratio (RR) for
HIV incidence being 0.97 (95% CI 0.81, 1.2) [24]. A com-
bination of mass treatment and STI management trials
showed a significant (12%) reduction in the prevalence of
syphilis for those receiving a biomedical STI intervention
(RR 0.88, 95% CI 0.80, 0.96) [24]. These interventions
also showed a significant 51% reduction in the prevalence
of Gonorrhoea (RR 0.49, 95% CI 0.31, 0.77), while no
improvement was observed in Chlamydia (RR 1.03, 95%
CI 0.77, 1.4) [24]. These findings suggest that effective
interventions can prevent the spread of infection, if
undertaken in reproductive age. Mass treatments and
behavioural interventions to increase awareness can sig-
nificantly reduce the incidence of STI while biomedical
STI interventions can reduce the incidence of gonor-
rhoea, and chlamydia.
Peri-conceptual folic acid supplementation for preventing
neural tube defects (NTDs)
Use of folic acid three months before conception to three
months after conception, is known to reduce the risk of a
first occurrence and a recurrence of NTDs [25,26]. Folic
acid deficiency has been linked to adverse outcomes of
pregnancy like LBW, antepartum haemorrhage and peri-
natal mortality [27]. It is recommended that all women of
childbearing age should consume 0.4 mg of folic acid per
day for the purpose of reducing the risk of a pregnancy
with NTDs [28]. During pregnancy, the requirement may
go up to at least 600 mcg, or even more up to 1000 mcg.
Studies suggest that the use of folic acid is highly effec-
tive for the prevention of recurrent NTDs (RR 0.30; 95%
CI: 0.14, 0.65) [29]. A Cochrane review also reported a
protective effect of daily folic acid supplementation
(alone or in combination with other vitamins and miner-
als) in preventing NTDs compared with no interven-
tions/placebo or vitamins and minerals without folic acid
(RR 0.28, 95% CI 0.15, 0.52) [30]. It is also shown to have
some non-significant impact on the reduction of miscar-
riage (RR 1.10; 95% CI: 0.97, 1.26) [30] and stillbirth (RR
0.96; 95% CI: 0.51, 1.83) [30]. A meta-analysis of peri-
conceptual folic acid fortification studies found reduction
in primary incidence of NTDs by 41% (RR 0.59; 95% CI
0.52, 0.68] [31]. Findings suggest that periconceptional
folic acid have a significant protective effect on NTDs,
particularly in women who had a previous pregnancy
affected by it (recurrent NTDs). New methods for the
provision of folic acid are underway which includes the
addition of folic acid in oral contraceptives. All women
with a history of baby with NTDs should be advised and
given folate to prevent its recurrence. Evidence from
Cochrane review is weak regarding the impact of folic
acid supplementation on stillbirths and miscarriages.
Pregnancy interventions
Antenatal care visit model
The effectiveness of the content, frequency, and timing of
visits in currently recommended programs for routine
antenatal care is yet to be ascertained. Data from observa-
tional studies have shown that groups having more
antenatal-care visits have lower maternal, fetal, and neona-
tal morbidity and mortality than those who have fewer
antenatal-care visits [32]. Earlier review found no associa-
tion of perinatal mortality with reduced visits compared to
standard care (OR 1.06; 95% CI: 0.82, 1.36) [33]. However,
a recent Cochrane review found that perinatal mortality
was increased for those randomised to reduced visits
rather than standard care (RR 1.14; 95% CI: 1.00, 1.31). In
the subgroup analysis, for high-income countries (HICs)
the association was non-significant (RR 0.90; 95% CI 0.45,
1.80); but for LMICs perinatal mortality was significantly
higher in the reduced visits group (RR 1.15; 95% CI 1.01,
1.32) [34]. Perception of mothers for the quality of prena-
tal care was not affected by the number of visits (RR 1.0;
95% CI 0.98, 1.01) [34]. On the other hand, no difference
in the rate of preterm birth (RR 0.87; 95% CI 0.47, 1.60)
and LBW (less than 2500 g)(RR 1.03; 95% CI 0.73, 1.46)
were found between women who received group antenatal
care compared with women receiving standard one-to-one
care [35]. The number of antenatal care visits should be
based of how effectively interventions can be delivered in a
timely way during pregnancy because the purpose of rou-
tine antenatal care is to deliver effective and appropriate
screening, preventive, or treatment interventions.
Iron and folic acid supplementation during pregnancy for
maternal anaemia
During pregnancy, mothers who have iron deficiency
anaemia have shown to have inadequate weight gain
needed to maintain a healthy fetus; have weak immune
system causing them to be more prone to infections; have
heavy placentas; and are at a higher risk of neonates being
born either prematurely or with LBW [36-39]. It is sug-
gested that the high iron demand during pregnancy can-
not be fulfilled from diet alone, so iron supplementation is
vital in these months. Pregnant women are routinely pro-
vided with iron supplementation throughout pregnancy.
Along with this, other interventions are now being
employed in order to reduce iron deficiency and these
include iron fortification, health and nutritional education
and the control of parasitic infections along with increas-
ing sanitation standards [40].
Maternal outcomes are shown to be greatly improved with
iron supplementation. Women taking iron supplements
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were less likely to have LBW newborns (below 2500 g) com-
pared to controls (RR 0.81; 95% CI 0.68, 0.97) with greater
mean birth weight (mean difference (MD) 30.81g; 95% CI
5.94, 55.68) [41]. Preventive iron supplementation reduces
the risk of maternal anaemia at term by 70% (RR 0.30; 95%
CI 0.19, 0.46) and iron deficiency at term by 57% (RR 0.43;
95% CI 0.27, 0.66) [41]. Moderately significant evidence was
found by Yakoob et al. stating that daily iron supplementa-
tion resulted in 73% reduction in the incidence of anaemia
at term (RR 0.27; 95% CI: 0.17, 0.42) and 67% reduction in
iron deficiency anaemia at term (RR 0.33; 95% CI: 0.16, 0.69)
compared to no intervention/placebo [42]. A review on folic
acid supplementation during pregnancy showed no conclu-
sive evidence for the impact on pregnancy outcomes such as
preterm birth (RR 1.01; 95% CI 0.73, 1.38), and stillbirths/
neonatal deaths (RR 1.33, 95% CI 0.96, 1.85). However,
improvements were seen in the mean birth weight (MD
135.75g, 95% CI 47.85, 223.68) and reduction in the inci-
dence of megaloblasticanaemia (RR 0.21, 95% CI 0.11, 0.38)
[43]. Exiting evidence suggests that providing mothers with
iron supplementation during pregnancy reduces the risk of
being anaemic near or at term. Although periconceptional
folate supplementation has a clear protective benefit against
occurrence of NTDs, antenatal folate supplementation in
combination with iron or multivitamins has a limited role in
prevention of perinatal mortality or morbidity. There are
relatively few studies in this regard and a stronger recom-
mendation can be made when results of more studies will
be available.
Tetanus immunisation in pregnancy for preventing
neonatal tetanus
Neonatal tetanus is a form of generalised tetanus that has
a high fatality rate. It usually occurs through infection of
the unhealed umbilical stump, particularly when the
stump is cut with an unsterile instrument [44]. Neonatal
tetanus presents mostly (90%) during the first 3-14 days
of life with the majority presenting at 6-8 days. The clini-
cal presentation is very distressing and the case fatality
rates tend to be very high even if full intensive care facil-
ities are available. Therefore preventive measures are
more effective than treatment options [45,46].
A Cochrane review by Dimecheli 2013, found 2 very old
trials (one on non-pregnant women). One trial compared
the effectiveness of tetanus toxoid with influenza vaccine
and reported a non-significant reduction in neonatal deaths
(RR 0.57; 95% CI: 0.26, 1.24) and 43% vaccine effectiveness
[47]. Another trial assessed the effectiveness of tetanus-
diphtheria toxoid in comparison with cholera toxoid in
preventing neonatal mortality by 80% (RR 0.20; 95% CI
0.10, 0.40) with vaccine effectiveness as 80% [47].However,
Blencowe 2010, added one well controlled cohort with one
controlled trial and found a significant reduction in neona-
tal tetanus mortality by 94% (RR 0.06; 95% CI 0.02, 0.20)
[48]. Despite the available low cost immunisation and
feasibility of reaching high coverage even in weak health-
care systems, the expected reduction in tetanus neonatal
mortality has not been achieved yet. It is expected that
with recent investments in the campaign for maternal and
neonatal tetanus elimination, there will be substantial pro-
gress in reduction of mortality due to this illness.
Prevention and management of malaria in pregnancy
Prevention of malaria in pregnancy is especially important
because most of these infections remain asymptomatic,
and therefore remain undetected and untreated [49].
There is a three-pronged approach to control malaria in
pregnancy as suggested by WHO: it includes the use of
insecticide-treated nets (ITNs) and antimalarial drugs,
either through intermittent preventive therapy (IPT) or
case management [50].
i) Prophylactic antimalarial for prevention of
malaria in pregnancy
For malaria prophylaxis, IPTp with sulfadoxine-pyri-
methamine (SP) is recommended for all pregnant
women at each scheduled antenatal care visit. WHO
recommends a schedule of four antenatal care visits.
- The first IPTp-SP dose should be administered as
early as possible during the 2ndtrimester of gestation
- Each SP dose should be given at least 1 month apart
- The last dose of IPTp with SP can be administered
up to the time of delivery, without safety concerns
An unpublished meta-analysis by Kayentao et al. exam-
ined the number of IPTp doses that need to be adminis-
tered during pregnancy to achieve the maximal beneficial
effects of IPTp. The meta-analysis claimed that 3 or
more doses (median of 4 doses) of IPTp with SP was
superior to the standard 2 dose regimen in preventing
LBW rates (reduction of 21% (95% CI 8, 32%) both in
HIV infected and uninfected pregnant women and in all
gravidity groups. Furthermore, women who received a
median of 4 doses of IPTp-SP compared to those on the
2-dose regimen also had a lower risk of moderate-severe
maternal anaemia, maternal malaria at delivery, and pla-
cental malaria. The meta-analysis, which included two
trials in areas of Burkina Faso and Mali where the effi-
cacy of SP remains high, showed that even in areas of
high SP efficacy, 3 doses of SP were more effective than
two doses [51]. Antimalarial drugs did not show
improvements in reducing maternal deaths (RR 0.34; 95%
CI: 0.04, 3.27) or perinatal deaths (RR 1.02; 95% CI: 0.73,
1.43) [52]. Routine antimalarial drugs reduce antenatal
parasitaemia when given to pregnant women in malaria
endemic areas. Greater benefit is seen in primi- and
secundi-gravidas. SP regimen is feasible, though their
regular use may precipitate increased risk of resistance. It
is also associated with lower incidence of LBW (35%) and
all-cause child mortality (18%). Two-dose IPT with SP
when compared with placebo in women during their first
or second pregnancy was found to reduce placental
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malaria (RR 0.48; 95% CI: 0.35, 0.68), LBW (RR 0.71;
95% CI: 0.55, 0.92), and anaemia (RR, 0.90; 95% CI: 0.81,
0.99) [53].
ii) Insecticide treated bed nets for preventing
malaria in pregnancy
An insecticide-treated net (ITN) is a mosquito net that
repel/disables and/or kills mosquitoes coming into con-
tact with insecticide on the netting material. All mos-
quito nets act as a physical barrier, preventing access by
vector mosquitoes and thus providing personal protec-
tion against malaria to the individual(s) using the nets. By
reducing the vector population, ITNs, when used by a
majority of the target population, provide protection for
all people in the community, including those who do not
themselves sleep under net. There are two categories of
ITNs: conventionally treated nets and long-lasting insec-
ticidal nets.
Langeler etal.conducted a review of five trials which
showed that ITNs provided 17% protective efficacy (PE)
compared to no nets (RR 0.83, 95% CI 0.76, 0.90), and
23% PE compared to untreated nets (RR 0.77, 95% CI
0.63, 0.95). About 5.5 lives (95% CI 3.39, 7.67) can be
saved each year for every 1000 children protected with
ITNs [54]. Results by Gamble at al. show that ITNs, com-
pared with no nets, reduced placental malaria in all preg-
nancies (RR 0.79, 95% CI 0.63, 0.98). They also reduced
LBW (RR 0.77, 95% CI 0.61, 0.98) and fetal loss in the
first to fourth pregnancy (RR 0.67, 95% CI 0.47, 0.97), but
not in women with more than four previous pregnancies.
It reduces peripheral and placental parasitaemia by 23%
(RR 0.77; 95% CI 0.66, 0.90) [55,56], increases mean birth
weight by 55g (95% CI 21, 88) [55,56], and decreases the
risk of fetal loss in the by 33% (RR 0.67; 95% CI 0.47,
0.97) [55,56]. Eisele et al. estimated that malaria preven-
tion interventions in pregnancy (IPTp and ITNs) have a
pooled PE of 35% (95% CI: 23-45%) for reducing the pre-
valence of LBW in the first or second pregnancy in areas
of stable P. falciparum transmission [57]. ITNs, therefore,
should be an integral part of strategies to prevent malaria
in pregnant women living especially in areas where
malaria is endemic.
Smoking cessation in pregnancy for improving birth
outcomes
Smoking during pregnancy has serious consequences on
the health and wellbeing of the newborn child. It has
important deleterious effects on the baby at birth and
throughout the early development of the child. The smok-
ing cessation strategies in pregnancy include provision of
advice and counselling using various tools (written and
electronic resources and telephone support), cognitive
behavioural therapy (CBT) and motivational interviewing,
advice and counselling based on feedback of fetal health
status or measurement of by products of tobacco smoking
in the mother, provision of pharmacological agents such
as nicotine replacement therapy and bupropion, social
support and encouragement, including the use of rewards
for cessation and other interventions such as hypnosis.
Smoking cessation programs in pregnancy have shown
to reduce smoking in late pregnancy (RR 0.94, 95% CI:
0.93 to 0.96) [58]. This also has an impact on reducing
LBW (RR 0.83, 95% CI 0.73 to 0.95) and preterm birth
(RR 0.86, 95% CI 0.74 to 0.98), with a 53.91g (95% CI
10.44, 95.38 ) increase in mean birth weight [58]. However,
the difference in smoking cessation in later pregnancy
after using nicotine replacement therapy was not signifi-
cant when compared with placebo group (RR 1.33, 95% CI
0.93, 1.91) [59]. It is important that smoking cessation pro-
grams be implemented in all maternity care settings.
Smoking cessation and relapse prevention strategies
should be routine parts of antenatal care as, for example,
the measurement of blood pressure. Counselling and con-
vincing patients for smoking cessation is a difficult job and
it should be emphasized that midwives, general practi-
tioners, and obstetricians support population-wide strate-
gies for smoking control in the whole community to
reduce/prevent/stop smoking by young people.
Prevention and management of syphilis
Maternal syphilis is related with adverse outcome in new-
borns. In 2008, the WHO estimated that 1.86 million
cases of syphilis occur globally among pregnant women
each year and that a large proportion of them are
untreated or inadequately treated. Up to one third of the
women attending antenatal care (ANC) clinics are not
tested for syphilis [60].
Treatment of syphilis is associated with a reduction in
preterm delivery (RR 0.36; 95% CI: 0.27, 0.47) [61].
Observational studies have shown a reduction in still-
births and neonatal mortality (RR 0.18; 95% CI: 0.10, 0.33
and RR 0.20; 95% CI: 0.13, 0.32 respectively) [61]. Review
by Walker at al.did not find studies that met predeter-
mined criteria for comparison, however, they did con-
clude that penicillin are effective in treating syphilis but
more studies are needed to establish the most effective
dosage and duration of therapy [62]. According to the
CDC guidelines, the treatment of syphilis during preg-
nancy includes penicillin and the doses depend upon the
stage of syphilis [63]. For primary, secondary, and early
latent syphilis the recommendation is to give benzathine
penicillin-G 2.4 million units intramuscular in one dose.
For females with late latent syphilis or latent syphilis with
unknown duration the recommendation is for 7.2 million
units of benzathine penicillin G administered as three
doses (2.4 million units per dose) given intramuscularly
for three weeks. The review on antibiotics given for the
management of syphilis did not have any trial that met
the eligibility criteria. However, observational studies
showed benefits in lowering the incidence of neonatal
mortality and preterm delivery.
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Prevention and management of HIV and prevention of
mother to child transmission (PMTCT) in pregnancy
Antiretroviral (ARV) drugs reduce viral replication and
can reduce mother-to-child transmission of HIV either by
lowering plasma viral load in pregnant women or through
post-exposure prophylaxis in their newborns. In rich
countries, highly active antiretroviral therapy (HAART)
which usually comprises three drugs has reduced the
mother-to-child transmission rates to around 1-2%. New
evidence published in Lancet Infectious Diseases based on
the Kesho Bora Studies state the giving a combination of
three ARV drugs to pregnant mothers with HIV infection
fromthelasttrimester, through delivery and six months of
breastfeedingreducestheriskof transmitting HIV to the
baby and improves survival. Infants of mothers whose
virus is fully suppressed (undetectable) by triple-ARVs at
the time of delivery have a very low risk of HIV infection
(only 2.7% by the age of one year). It is therefore impor-
tant to start ARVs early in pregnancy, ideally before preg-
nancy, for all women who require antiretroviral treatment
(ART) (CD4 count at or below 350 cells/mm3). Giving
HIV-positive pregnant women and that planning preg-
nancy priority access to HIV testing, CD4 count and
ARVs will help eliminate mother-to-child transmission of
HIV [64].
Vitamin A supplementation was found to reduce the
risk of HIV infection in child (RR 1.04; 95% CI: 0.87, 1.24)
[65] thus being useful for PMTCT. Vaginal disinfection,
on the other hand, did not find any impact on reducing
the transmission of HIV to child (RR 0.93; 95%CI 0.63,
1.38) [66].
A new study led by the WHO’s Department of Repro-
ductive Health and Research shows that if HIV-positive
pregnant women are given a combination of antiretroviral
(ARV) drugs from late in pregnancy until six months into
breastfeeding, rather than a short course of drugs that
ends at delivery, the likelihood of their babies becoming
infected with HIV are over 40% lesser than with no such
treatment [67].
The Kesho Bora study shows that a significant reduction
in infant infection can be achieved when pregnant women
with a CD4 immune cell count of 200-500 cells/ mm3 are
given a combination of three ARVs to prevent transmis-
sion. This treatment should start in their last trimester of
pregnancy, continuing through birth and six months of
breastfeeding. This was shown to reduce the risk of trans-
mitting HIV to the baby and improved survival compared
with babies of mothers with HIV who are given the cur-
rent WHO-recommended short-course ARV regimen in
late pregnancy and around the time of delivery. An infant
of mothers whose virus is fully suppressed undetectable by
triple-ARVs at the time of delivery has a very low risk of
HIV infection (only 2.7% by the age of one year). It is
therefore important to start ARVs early in pregnancy,
ideally before pregnancy, for all women who require anti-
retroviral treatment (ART) (CD4 count at or below
350 cells/mm3). Giving HIV-positive pregnant women
and those planning pregnancy priority access to HIV test-
ing, CD4 countand ARVs will help eliminate mother-to-
child transmission of HIV [67].
The review by Read et al. identified 6 RCTs, of which,
one RCT was on the efficacy of elective caesarean sec-
tion (ECS) for prevention of MTCT of HIV-1. Among
HIV-1-infected women not taking antiretroviral (ARVs)
during pregnancy or taking only zidovudine, ECS was
found to be efficacious for prevention of MTCT of
HIV-1 [68].
Calcium for hypertension in pregnancy
Hypertension, with or without proteinuria, is an important
cause of maternal and perinatal mortality and morbidity
globally [69,70]. It complicates pregnancy and is responsi-
ble for maternal deaths [71]. Therefore, strategies to
reduce the risk of these hypertensive disorders should be
given high priority to save thousands of lives of mothers,
especially in developing countries.Based on observations
of communities in Guatemala and Ethiopia, it has been
seen that women with a high calcium intake in their diet
have a lower prevalence of pre-eclampsia and eclampsia
[72]. This was further supported by other epidemiological
and clinical studies [72-75]. A possible mode of action of
calcium could be that it reduces parathyroid hormone
release and intracellular calcium, and so decreases smooth
muscle contractility and, therefore, vasoconstriction
[76,77]. Calcium can also act directly on uterine smooth
muscle to reduce contractility and prevent pre-term labour
and delivery [76,77].
Calcium supplementation can be an attractive, poten-
tial intervention to reduce the risk of a woman develop-
ing pre-eclampsia.
All studies showed that calcium supplementation has an
effect on the reduction of pre-eclampsia (RR 0.45; 95% CI:
0.31, 0.65) [78].Hofmeyer 2007 also showed that high
blood pressure was reduced with calcium supplementation
when compared with placebo (RR 0.65, 95% CI 0.53, 0.81),
as was pre-eclampsia (RR 0.48; 95% CI 0.33, 0.69) [79].
The effect was greatest for women at high risk (RR 0.22;
95% CI 0.12, 0.42) and for those with low baseline calcium
intake (RR 0.36; 95% CI 0.18, 0.70) [79,80]. The composite
outcome maternal death or serious morbidity was reduced
(RR 0.80; 95% CI 0.65, 0.97). There was no overall effect
on the risk of preterm birth or stillbirth or death before
discharge from hospital [79,80]. Jabeen et al. showed
borderline reduction in stillbirths (RR 0.81, 95 % CI 0.63,
1.03)with calcium supplementation [81].
Calcium supplementation significantly reduced the
risk of pre-eclampsia by 55% and by 64% in women
with low dietary intake of calcium. It also had a signifi-
cant protective effect on maternal mortality and serious
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morbidity and preterm birth. Its effect on, LBW or still-
birth was, however, non-significant. More large-scale
trials need to be conducted to assess its safety profile
before it can be routinely introduced into clinical
practice.
Anti-platelet agents (low dose aspirin) for prevention of
pre-eclampsia
Pre-eclampsia also leads to deficiency of prostacyclin, a
vasodilator, and produces excessive amounts of throm-
boxane, which acts by stimulating platelet aggregation
and causing platelet derived vasoconstriction [82]. It is
due to these observations that it is said the anti-platelet
agents, especially low dose aspirin, can prevent or delay
the development of pre-eclampsia.
The results show that that when anti-platelet agents are
given during pregnancy, it leads to consistent reduction
in the risk of preterm births (<34 weeks) (RR 0.92, 95%CI
0.88, 0.97), pre-eclampsia (RR 0.83, 95% CI 0.77, 0.89)
and other adverse effect of pregnancy [83]. Importantly
for the fetus there was a significant reduction of 17% in
all types of deaths (fetal, neonatal, infant) (RR 0.86, 95%
CI 0.76, 0.98) [83]. It is also noted that anti-platelet
agents given to pregnant mothers who had gestational
hypertension benefit even more with a significant reduc-
tion of 40% in the incidence of pre-eclampsia (RR 0.60
95%CI 0.45, 0.78) [83]. On the other hand, a review Jab-
een et al. did not show significant impact on reducing the
risk of stillbirths (RR 1.15; 95% CI: 0.88, 1.49) [81].
Another review also reported reduce incidence of pre-
eclampsia with anti-platelet agents (RR 0.90, 95% CI 0.84,
0.97) [84].
We would recommend that anti-platelet agents should
be given to pregnant women at high risk of pre-eclampsia
or those with gestational hypertension, since they lead to
reduction of vast adverse outcomes of pregnancy both
for the mother and newborn.
Anti-hypertensive for treating severe hypertension
Hypertensive disorders of pregnancy, as a group, are a
major cause of maternal and perinatal morbidity and
mortality in both developing and the developed world
[85,86]. The International Society for the Study of Hyper-
tension in Pregnancy defines hypertension as a diastolic
blood pressure of 90 mmHg or above on two consecutive
occasions at least four hours apart, or a single diastolic
blood pressure of 110mmHg or more [87].
Women allocated calcium channel blockers rather than
hydralazine were less likely to have persistent high blood
(RR 0.37, 95% CI 0.21, 0.66) [88]. Ketanserin was found
to be associated with more persistent high blood pressure
than hydralazine (RR 4.79, 95% CI 1.95, 11.73), but fewer
side-effects (RR 0.32, 95% CI 0.19, 0.53). Both nimodipine
and magnesium sulphate were associated witha high inci-
dence of persistent high blood pressure, but a single
study showed that this risk was lower for nimodipine
compared to magnesium sulphate (RR 0.84, 95% CI 0.76
to 0.93) [88]. Oral beta-blockers decrease the risk of
severe hypertension (RR 0.37, 95% CI 0.26 to 0.53) and
the need for additional antihypertensive (RR 0.44, 95% CI
0.31 to 0.62) [89].
The rationale for giving anti-hypertensive is that they
will be dilatory in progression to severe disease with dras-
tic complications for the mother and her baby. They may
also reduce the risk of preterm delivery and placental
abruption and improve fetal growth. Until better evi-
dence is available, the choice of antihypertensive should
depend on the clinician’s experience and familiarity with
a particular drug and on what is known about adverse
effects. Exceptions are diazoxide, ketanserin, nimodipine
and magnesium sulphate, which are probably best
avoided. The use of antihypertensive for treating severe
hypertension in pregnant women is likely to bring an
improvement in the neonatal and maternal outcomes.
Management of pregnancy-induced hypertension (PIH)/
eclampsia
Pre-eclampsia is defined as a disorder during pregnancy
with raised blood pressure and proteinuria, which may
involve multiple systems including liver, kidneys, clotting
system and brain. If it is complicated by convulsions (fits),
then the condition is called eclampsia. Anticonvulsants
like magnesium sulphate are used for eclamptic seizures
and were introduced for women with pre-eclampsia in the
belief that they would prevent the onset of seizures. This
profile compares magnesium sulphate with other agents
like diazepam, phenytoin and lytic cocktail for control of
eclampsia; and also reviews the pros and cons of using it
in women with pre-eclampsia as a prophylaxis vs. no
anticonvulsants.
Magnesium sulphate therapy usually starts with an
intravenous loading dose usually 4g but some advocate
6g, with therapy being continued either for 24 hours in
total or until 12 to 24 hours after delivery. This is fol-
lowed by either intramuscular (IM) or intravenous (IV)
maintenance therapy. The IM maintenance regimen is
usually 10 g given with the loading dose, and then 5 g
every four hours. The IV infusion is usually 1 g/hour,
although 2 g/hour is used by some.
Magnesium sulphate for pregnancies with pre-eclamp-
sia had a significant impact on reducing stillbirths (RR
0.99; 95% CI: 0.87, 1.12) when compared with placebo/no
treatment [81]. When comparing magnesium sulphate to
diazepam, magnesium sulphate was associated with a
reduction in maternal death (RR 0.59, 95% CI 0.38, 0.92)
and recurrence of seizures (RR 0.43, 95% CI 0.33, 0.55)
[90]. When compared with phenytoin, magnesium sul-
phate was associated with a substantial reduction in the
recurrence of seizures (RR 0.34, 95% CI 0.24, 0.49). The
trend in maternal mortality favours magnesium sulphate,
but the difference does not reach statistical significance
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(RR 0.50, 95% CI 0.24, 1.05) [91]. On the other hand,
when magnesium sulphate was compared with placebo
or no anticonvulsant, it led to halved the risk of eclamp-
sia (RR 0.41, 95% CI 0.29, 0.58), with a non-significant
reduction in maternal death (RR 0.54, 95% CI 0.26, 1.10)
but no clear difference in serious maternal morbidity (RR
1.08, 95% CI 0.89, 1.32) [92]. Magnesium sulphate was
also compared with lytic cocktail and it was associated
with fewer maternal deaths (RR 0.14, 95% CI 0.03, 0.59)
and was better at preventing further seizures (RR 0.06,
95% CI 0.03, 0.12) than lytic cocktail [93].
Magnesium sulphate is an inexpensive drug and can be
conveniently used in low income countries. Our review
indicates that this drug significantly reduces the progress
to eclampsia when given to women with pre-eclampsia
compared to placebo. It should, therefore, be considered
for those pre-eclamptic cases where there is a concern
about the development of eclampsia. Clinical monitoring
is necessary and can be achieved if trained staff is available.
Serum monitoring is not necessary. For eclampsia, magne-
sium sulphate is now preferred over diazepam, phenytoin
or lytic cocktail. It is significantly better in preventing
maternal mortality and recurrence of seizures.
External cephalic version for breech presentation at term
(>36 weeks)
Malpresentation places a healthy fetus and mother at
increased risk of a complicated vaginal birth or caesarean
section. It is not surprising that, over the years, the possi-
bility of turning the baby from the breech to the cephalic
presentation (ECV) has intrigued some obstetric care-
givers. Before the mid-1970s, ECV was usually attempted
before term because of the belief that the procedure
would seldom be successful at term. Subsequent studies
showed that with the use of tocolysis, ECV could be
achieved in a substantial proportion of women with
breech presentation at term (37 completed weeks of
pregnancy or more). Predictors of unsuccessful version
include engaged presenting part, fetal head not easily
palpable and tense uterus [94].
Tocolytic drugs, in particular beta stimulants, were
effective in increasing cephalic presentations in labour by
38% (RR 1.38, 95% CI 1.03,1.85) and in reducing the num-
ber of caesarean sections by 18% (RR 0.82, 95% CI 0.71,
0.94) [95]. Initially, successful ECV at a late stage of preg-
nancy was considered to have become possible only
because of the use of tocolytic drugs to relax the uterus.
However, later studies showed that ECV at term was fre-
quently possible without tocolysis. The overall success rate
was 60% in a systematic review of RCTs where some trials
included facilitation and others did not [96].
When postural management with pelvic elevation for
breech presentation was compared with a control group
reported the similar rates for non-cephalic births,
caesarean section and Apgar scores below 7 at one min-
ute, regardless of whether ECV was attempted or not(RR
0.98; 95% CI 0.84, 1.15; RR 1.10; 95% CI 0.89, 1.37; RR
0.88; 95% CI 0.50, 1.55 respectively)[97]. When compar-
ing births with ECV for term births, no significant differ-
ences in the incidence of Apgar score ratings below
seven at one minute (RR 0.95, 95% CI 0.47, 1.89) or five
minutes (RR 0.76, 95% CI 0.32, 1.77), low umbilical artery
pH levels (RR 0.65, 95% CI 0.17, 2.44), neonatal admis-
sion (RR 0.36, 95% CI 0.04, 3.24), perinatal death (RR
0.34, 95% CI 0.05, 2.12), nor time from enrolment to
delivery (Weighted Mean Difference (WMD) -0.25 days,
95% CI -2.81 to 2.31) were found [98]. For term breech
delivery, perinatal or neonatal death (excluding fatal
anomalies) or serious neonatal morbidity was reduced
with planned caesarean section (RR 0.33, 95% CI 0.19,
0.56). This reduction was less for countries with high
national perinatal mortality rates [99]. Evidence exists in
which moxibustion has no impact in reducing the need
for ECV (RR 0.67 95% CI 0.34, 1.32) [100] but there is a
need for well-designed RCTs to establish further evi-
dence of the effectiveness of the intervention.
During an external cephalic version, practitioners use
their hands on the woman’s abdomen to gently try to turn
the baby from the breech position. There is sufficient evi-
dence to conclude that external cephalic version at term
reduces the chances of non-cephalic births and caesarean
sections. There is lack of evidence from RCTs to assess
the complication of cephalic version at term. Insufficient
evidence exists to support the use of moxibustion to cor-
rect breech presentation.
Management of preterm, premature rupture of membranes
A) Management of premature rupture of membranes
(PROM) (induction of labour)
Rupture of membranes before the onset of labour com-
plicates 5-10% of all pregnancies, referred to as PROM
(premature rupture of the membranes) [101]. A minimum
of 60% of these cases occur in pregnant women at term.
Infection can be cause or a consequence of PROM. One
way to prevent infections after PROM at term would be to
expedite delivery by inducing labour, in which case pre-
labour antibiotics may not be indicated. But in situations
where expectant management is preferred, antibiotics may
be beneficial in terms of reducing the likelihood of infec-
tion in the mother and her baby. This review compiles the
existing evidence on the benefits and risks of the use of
antibiotics in PROM at or near term.
Early delivery increased the incidence of caesarean sec-
tion (RR 1.51; 95% CI 1.08, 2.10). There was no difference
in the overall perinatal mortality (RR 0.98, 95% CI 0.41,
2.36), intrauterine deaths (RR 0.26;95% CI 0.04, 1.52) or
neonatal deaths (RR 1.59, 95% CI 0.61, 4.16) when com-
paring early delivery with expectant management [102].
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There is insufficient evidence to guide clinical practice on
the benefits and harms of immediate delivery compared
with expectant management for women with PPROM.
B) Management of preterm, premature rupture of
membranes (PPROM) (use of antibiotic)
Management of PROM includes administration of any
antibiotic for women with PPROM, inculcating all beta-
lactam antibiotics (including penicillin) and macrolides.
The use of antibiotics was associated with a statistically
significant reduction in chorioamnionitis(RR 0.66, 95%
CI 0.46, 0.60) [103], preterm birth (RR 0.79, 95% CI 0.71,
0.89) [103] and neonatal infections including pneumonia
(RR 0.67, 95% CI 0.52, 0.85) [103], which would support
their routine clinical use in cases of pPROM. It did not,
however, significantly impact perinatal mortality and
neonatal mortality. Cousenset al. included 18 RCTs from
high-income countries and provided strong evidence that
antibiotics for pPROM reduce the risk of respiratory dis-
tress syndrome (RR 0.88; 95% CI 0.80, 0.97), and early
onset postnatal infection (RR 0.61; 95% CI 0.48, 0.77)
[104]. The data was also found to be consistent with a
reduction in neonatal mortality (RR 0.90; 95% CI 0.72,
1.12) [104].
Any antibiotics, administered as prophylaxis, by any
route, to women at gestational age 36 weeks or beyond,
with premature rupture of the membranes, can be used
to manage this condition. There is not enough evidence
to recommend routine use of antibiotics in women with
PROM at term, although there was a 36% reduction in
chorioamnionitis. Antibiotics may be reserved only for
women that develop clinical indications of an infection,
rather than prescribing it for all women in general. There
were no clear neonatal advantages either. More trials are
needed to evaluate their use, especially in women with
PROM with expectant management or with a policy of
delayed induction.
C) Corticosteroid use in preterm labour
One of the gravest outcomes of preterm labour is
babies being born with respiratory distress syndrome
(RDS), as this is the primary cause of early neonatal
death and disability [105]. RDS occurs as a complication
of preterm delivery and it is present in about 20% of
LBW babies (<2500g) and about 66% of extremely LBW
babies (<1500g) [105]. The reason for the development of
RDS is a combination of poor lung development, imma-
turity of organs and a deficiency of surfactant. The role
of corticosteroids when given prior to preterm birth
shows that they can decrease the incidence of RDS and
neonatal mortality in babies [106]. This occurs from the
theory that steroids can cause premature liberation of
surfactant by alveoli and the surfactant produced will
help in preventing the alveoli from collapsing. In the
absence of surfactant the alveoli collapse during expira-
tion and the following inspiration needs more effort to
open the alveoli. If there is no surfactant this cycle of the
alveoli collapsing continues and finally leads to fatigue,
decreased respiratory effort, hypoxia, cyanosis, acidosis,
and eventually death [107].
Antenatal steroids decrease neonatal mortality among
preterm infants (<36 weeks gestation) by 31% (RR 0.69;
95% CI 0.58, 0.81). RCTs from middle-income countries
suggests 53% mortality reduction (RR 0.47; 95% CI 0.35,
0.64) and 37% morbidity reduction (RR 0.63; 95% CI
0.49, 0.81) [108]. Treatment with corticosteroids showed
a statistically significant reduction of 23% in combined
incidence of fetal and neonatal deaths (RR 0.77, 95%CI
0.67, 0.89), and this result was mainly due to the reduc-
tion seen in neonatal deaths (RR 0.69, 95% CI 0.58,
0.81). Antenatal corticosteroids were tested for the
reduction ofmaternal death but the result failed to reach
statistical significance (RR 0.98, 95% CI 0.06, 15.50)
[105].There was also a significant reduction in the inci-
dence of RDS (RR 0.66, 95% CI 0.59,0.73),moderate to
severe RDS(RR 0.55, 95% CI0.43, 0.71),cerebroventricu-
lar haemorrhage (CVH) and severe CVH (RR 0.54, 95%
CI 0.43, 0.69) [105]. A Cocharane review of 10 trials
showed that dexamethasone decreased the incidence of
intraventricular haemorrhage compared with betametha-
sone (RR 0.44, 95%CI 0.21, 0.92) [109].
Management of unintended pregnancy
Numbers of unsafe abortions have increased from
19.7million in 2003 although the overall unsafe abortion
rate remains unchanged at about 14 unsafe abortions per
1000 women aged 15–44 years [14]. WHO defines these
abortions as procedures that women undergo in order to
terminate an unwanted pregnancy either in surroundings
that are far below the medical standards or done by
unskilled individuals, or both [110]. The reasons for high
rates of unsafe abortions in the developing world are that
in some countries abortions are considered illegal or
legal abortions are not offered, forcing females with
unplanned pregnancy to either obtain secret abortions by
untrained medical workers or self-induce abortions lead-
ing to the risk of complications. Females who undergo
unsafe abortions are at the risk of developing complica-
tions which in most cases lead to long hospital stay and
can also lead to mortality. It is stated that the commonest
causes of mortality in females undergoing unsafe abor-
tions are haemorrhage, infections and, in some cases, poi-
sons that were used in self-inducing abortions [111]. It is
reason like these that makes it vital for clinics and hospi-
tals, especially those in the developing countries, to have
proper post-abortion care for patients. The fundamentals
of post-abortion care should include having a medical
staff skilled enough to handle all types of complications,
along with having facilities for uterine evacuation proce-
dures, along with referral of all patients to advanced sex-
ual and reproductive health services. Lastly, females
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should be provided with counselling on contraceptives,
family planning and told about the risks of unsafe abor-
tions [112].
Another option to decrease the number of unsafe abor-
tions and its complications would be by legalizing abor-
tions, along with promoting the use of contraceptives or
providing females proper counselling on these topics. It
is seen that in those countries where abortion is legalized,
mortality has considerably declined. This notion would
be highly recommended for all developing nations where
abortion is still not legalized, especially countries where
religious prohibition and social norms do not allow this
to occur.
According to the WHO guidelines on safe abortion
2003 [113], abortion services should be provided by
well-trained health personnel to pregnant women who
elect for the procedure. It must be supported by poli-
cies, regulations and a health systems infrastructure,
including equipment and supplies, so that women can
have rapid access to these services.
Cross cutting interventions
Home visits for women and children across the
continuum of care
It is difficult to provide expert medical care to each and
every person at community level especially in developing
countries. To support the basic primary health care infra-
structure, different community based intervention
packages have been introduced to train persons in the
society who has some background medical knowledge e.g.
community health workers. These individuals with proper
training, can function as community activists, opinion lea-
ders, or health promoters, and can share their knowledge
with community members, including pregnant women
and their families. However as the background of each
community health worker is different, a particular inte-
grated approach could not be developed with public sector
programs to target a particular goal. Different community
based intervention packages have been developed to train
community health workers for specific tasks like antenatal
and postnatal care etc. [114,115].
Improved perinatal care practices led to a drop in
maternal mortality rate (OR 0.62; 95% CI 0.39, 0.98)
[116]. Home based Neonatal care packages led to a
decrease in perinatal mortality (RR 0.71; 95% CI 0.61,
0.84) [114]; as well as incidence of stillbirths (RR 0.87;
95% CI 0.73, 1.03) [115]. Another review showed a reduc-
tion in neonatal mortality (RR 0.76; 95% CI 0.68, 0.84) as
well as incidence of stillbirths (RR 0.84; 95% CI 0.74,
0.97) and perinatal mortality (RR 0.80; 95% CI 0.71, 0.91)
[117]. The intervention packages included home visits
during the neonatal period, home-based treatment for ill-
ness and community mobilization efforts showed a
reduced risk of neonatal death (RR: 0.62; 95% CI 0.44,
0.87) and stillbirth (RR: 0.76; 95% CI 0.65, 0.89) [118].
The available data suggests that introduction of com-
munity based intervention packages can improve mater-
nal and neonate survival. The results from Cochrane
review are very promising and showed impact on redu-
cing stillbirths, perinatal mortality and neonatal
mortality.
Discussion
The review aimed to document the essential pre-
pregnancy and pregnancy interventions for improved
maternal, newborn and child health. It covers pre-
pregnancy interventions including family planning, pre-
vention and management of STI and HIV and folic acid
suuplementation prior to pregnancy amongst other
interventions. In order to achieve maximum impact of
pre-pregnancy interventions, these interventions should
be appropriately timed [119]. With regards to antenatal
care, calcium and magnesium supplementation for pre-
vention and management of pre-eclampsia and prophy-
lactic and therapeutic uterotonics for prevention of
postpartum heamorrahge are a couple of effective inter-
ventions that have the potential to save many maternal
lives and prevent poor pregnancy outcomes. The imple-
mentation of the interventions reviewed in this paper
will provide to be of paramount importance to improv-
ing the maternal and neonatal statistics especially in the
developing countries, where there is a lot of potential
work to be done. It is vital to understand that these
interventions are central for LMIC where maternal and
child health indicators are still not up to the standards
and many lives are either lost or their quality compro-
mised owing to a dearth of provision of essential inter-
ventions [120].
This review was designed to serve as a comprehensive
and thorough document of essential pre-pregnancy and
pregnancy interventions which could be used by both clin-
icians and policy makers. The review included all the
recent Cochrane and non Cochrane reviews on specific
interventions and the exercise included all essential pre-
pregnancy and pregnancy interventions for maternal, new-
born and child health. The data was summarized in a logi-
cal manner that can be utilized for further implementation
and policy making to enable improvement in current
health care system of LMICs. However, at times the qual-
ity of all included randomized controlled trials could not
be ensured which limited the quality of the data obtained.
Some reviews that were included were not updated
recently and the data extracted from them might reflect
facts that are not up to date. However, those reviews
which had been updated by the authors were revised and
the data extracted from within them was made up to date.
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As stated earlier, the review is meant to be useful for
health care practitioners as well as policy makers so that
they may integrate and plan these interventions not only
during the course of the pregnancy but also before preg-
nancy. It is essential to make policies and ensure that
these essential interventions are delivered in a timely
and effective manner.The integration of these interven-
tions in the existing health services can not only
improve outcomes presently but also lead to a better
future of health care settings for both mothers and neo-
nates. Long term sustainment of these improvements
are necessary, therefore, it is essential to evaluate the
impact of these interventions once streamlined into
existing packages and programs. The transition to
improved health care system must be made soon as it is
becoming increasingly important to deliver these inter-
ventions at a large scale. With the deadlines of MDGs
approaching upon us, immediate action is required to
discuss these issues at policy making levels as well, so
that we can find a way forward. Unless these problems
are actively pursed and the suggestions given a thought,
the issues related to maternal and newborn health care
will keep on lingering upon us. Therefore, the review
focuses on the approach which is critical to achieving
the MDGs 4 and 5 – ensuring that we not only save
lives to also address overall health and well-being.
Conclusion
Needless to say,the global cost for maternal disability is
very high, therefore, ensuring the prompt and effective
delivery of these interventions will be an effective strat-
egy at moving towards the achievement of the millen-
nium development and it would also lead to a much
needed decrease in the burden of disease related to
chronic complications of pregnancy and childbirth.
Quite promisingly, a decline of 47% is seen in the statis-
tics related to maternal mortality since the 1990s around
the globe. Most encouraging is the fact that since 1990,
some countries in Asia and Northern Africa have more
than halved the numbers related to maternal mortality.
These advancements herald atime when the achieve-
ment of MDGS 4 and 5 is closer than it has ever been
before. With the proper implementation of a set of
essential interventions recommended in this paper, we
can hope to see the promising status of both improved
and sustained maternal, neonatal and child helath out-
comes.The integration of the basic care recommended
and discussed in this paper with the global healthcare
settings will be an effective strategy towards attaining a
better health care setting for mothers and their children.
With each passing day, we must aim to build a future in
which each mother and child receives the best of health
care regardless of their financial status or the area in
which they reside. This could only be possible if there is
a global knowledge and implementation of thelife saving
interventions mentioned in this review.
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